Latest news with #MRCP
Business Wire
4 days ago
- Business
- Business Wire
MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) ('MAIA', the 'Company'), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced the appointment of two prominent oncologists to its Scientific Advisory Board (SAB), Claudia Fulgenzi, MD, and David J. Pinato, MD, MRCP (UK), PhD. Both are specialists in hepatocellular carcinoma (HCC), a tumor type to be studied in future clinical trials of MAIA's lead candidate ateganosine (THIO) sequenced with a checkpoint inhibitor. As SAB members they will advise MAIA on designs and protocols for its company sponsored trial (CST) in HCC and may participate in future investigator sponsored trials (IST). 'Drs. Pinato and Fulgenzi are scientific experts on inflammation as a pathogenic and prognostic mechanism in primary liver cancers. Together, their research has focused on improving the treatment of HCC, particularly with the use of anti-cancer immunotherapy,' said MAIA Chairman and CEO Vlad Vitoc, M.D. 'They will bring a wealth of knowledge to our SAB, with specialized expertise that will inform our plans and preparations for our upcoming clinical program in HCC. 'By the end of this year, we expect to have all required approvals to begin enrolling patients in a HCC trial,' Dr. Vitoc added. MAIA was granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for ateganosine as a treatment for HCC in 2022. ODDs can provide up to seven years of market exclusivity. Dr. David Pinato is a clinician scientist in the Department of Surgery and Cancer at Imperial College London and a consultant oncologist at Imperial College Healthcare NHS Trust. As Director of Developmental Cancer Therapeutics at Imperial College, he leads a translational research program focused on the early clinical implementation of novel experimental anticancer therapies with particular emphasis on anti-cancer immunotherapy. Dr. Pinato's research efforts in liver cancer have been recognized by the American Society of Clinical Oncology (ASCO) and the Society for Immunotherapy of Cancer (SITC). He has received awards by the British Society of Pharmacology and the Royal Society of Medicine, and fellowships by the European School of Oncology and Fulbright Program. Dr. Pinato completed his core medical training across some of the busiest acute hospitals in London and was elected to the Royal College of Physicians (MRCP). His research has been published in leading journals in the field including the Journal of Clinical Oncology, Annals of Oncology, Hepatology and many others. Dr. Pinato lectures internationally in the field of molecular oncology with a specific interest in HCC and acts as a reviewer for several peer-reviewed journals including The Lancet, Cancer Discovery, Hepatology and Journal of Hepatology. Dr. Claudia Fulgenzi is a specialist in medical oncology at Imperial College London, with dedicated professional interest in the field of immune-oncology and gastro-intestinal cancers, particularly hepatic-biliary malignancies. Dr. Fulgenzi graduated in medicine from the University of Rome Tor Vergata and subsequently specialized in medical oncology at the University Campus Bio Medico of Rome, Italy. Her contributions to the field have been recognized with prestigious awards including the ASCO Merit Award, the Young Investigator award by the International Liver Cancer Association (ILCA) and the American Society of Clinical Oncology. Dr. Fulgenzi is actively engaged in clinical practice in London, serving as an honorary consultant in oncology at Chelsea and Westminster Hospital and as a specialty doctor in the early phase clinical trial unit at Hammersmith Hospital. In these capacities, she conducts clinical and translational research, contributes to clinical trial design, and provides expert medical guidance to cancer patients. Hepatocellular carcinoma is the most frequently occurring primary liver tumor representing approximately 90% of all liver cancers. HCC currently ranks 5th by incidence and 3rd by mortality on a global scale. About Ateganosine Ateganosine (THIO, 6-thio-dG or 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2'-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit Forward Looking Statements MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as 'may,' 'might,' 'will,' 'should,' 'could,' 'expect,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'project,' 'intend,' 'future,' 'potential,' or 'continue,' and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, 'MAIA,' 'Company,' 'we,' 'our,' and 'us' refers to MAIA Biotechnology, Inc. and its subsidiaries.
The Sun
14-06-2025
- Health
- The Sun
Dr Wan Azizah conferred Eminent Educator Award from college of physicians Malaysia
PUTRAJAYA: Datuk Seri Dr Wan Azizah Wan Ismail, wife of the Prime Minister, was conferred the Eminent Educator Award by the Sultan of Perak, Sultan Nazrin Shah, from the College of Physicians Malaysia. The ceremony took place during the Inaugural Membership of the Royal College of Physicians (MRCP) and Parallel Pathway Conferment Ceremony held here today. During the event, Sultan Nazrin Shah presented the conferment certificate to the former Deputy Prime Minister. The Eminent Educator Award is the highest honour bestowed by the College of Physicians Malaysia, recognising exceptional contributions to education in parallel pathway medical training. 'Today, we are especially honoured to present the Eminent Educator Award to Dr Wan Azizah in recognition of her exemplary contibutions and steadfast support during the post-specialist training phase, support that has been instrumental to the success and longevity of the Parallel Pathway in Malaysia,' College of Physicians Malaysia, President, Datuk Seri Dr Paras Doshi said in his speech. Also present were the Chief Secretary to the Government, Tan Sri Shamsul Azri Abu Bakar, and Health Director-General Dr Mahathir Abd Wahab. Dr Wan Azizah holds a medical degree from the Royal College of Surgeons in Ireland and completed postgraduate training in Ophthalmology at the Royal College of Ophthalmologists (UK).
The Sun
14-06-2025
- Health
- The Sun
Datuk Seri Dr Wan Azizah Receives Eminent Educator Award
PUTRAJAYA: Datuk Seri Dr Wan Azizah Wan Ismail, wife of the Prime Minister, was conferred the Eminent Educator Award by the Sultan of Perak, Sultan Nazrin Shah, from the College of Physicians Malaysia. The ceremony took place during the Inaugural Membership of the Royal College of Physicians (MRCP) and Parallel Pathway Conferment Ceremony held here today. During the event, Sultan Nazrin Shah presented the conferment certificate to the former Deputy Prime Minister. The Eminent Educator Award is the highest honour bestowed by the College of Physicians Malaysia, recognising exceptional contributions to education in parallel pathway medical training. 'Today, we are especially honoured to present the Eminent Educator Award to Dr Wan Azizah in recognition of her exemplary contibutions and steadfast support during the post-specialist training phase, support that has been instrumental to the success and longevity of the Parallel Pathway in Malaysia,' College of Physicians Malaysia, President, Datuk Seri Dr Paras Doshi said in his speech. Also present were the Chief Secretary to the Government, Tan Sri Shamsul Azri Abu Bakar, and Health Director-General Dr Mahathir Abd Wahab. Dr Wan Azizah holds a medical degree from the Royal College of Surgeons in Ireland and completed postgraduate training in Ophthalmology at the Royal College of Ophthalmologists (UK).
New Straits Times
14-06-2025
- Health
- New Straits Times
Dr Wan Azizah conferred Eminent Educator Award from College of Physicians Malaysia
PUTRAJAYA: Datuk Seri Dr Wan Azizah Wan Ismail, wife of the Prime Minister, was conferred the Eminent Educator Award by the Sultan of Perak, Sultan Nazrin Shah, from the College of Physicians Malaysia. The ceremony took place during the Inaugural Membership of the Royal College of Physicians (MRCP) and Parallel Pathway Conferment Ceremony held here today. During the event, Sultan Nazrin Shah presented the conferment certificate to the former Deputy Prime Minister. The Eminent Educator Award is the highest honour bestowed by the College of Physicians Malaysia, recognising exceptional contributions to education in parallel pathway medical training. "Today, we are especially honoured to present the Eminent Educator Award to Dr Wan Azizah in recognition of her exemplary contibutions and steadfast support during the post-specialist training phase, support that has been instrumental to the success and longevity of the Parallel Pathway in Malaysia," College of Physicians Malaysia, President, Datuk Seri Dr Paras Doshi said in his speech. Also present were the Chief Secretary to the Government, Tan Sri Shamsul Azri Abu Bakar, and Health Director-General Dr Mahathir Abd Wahab. Dr Wan Azizah holds a medical degree from the Royal College of Surgeons in Ireland and completed postgraduate training in Ophthalmology at the Royal College of Ophthalmologists (UK).
Borneo Post
06-05-2025
- General
- Borneo Post
Kelabit community mourns loss of ‘bringer of good news'
Philip shows a newspaper clipping of the news article that Ritchie wrote about him in the New Straits Times. MIRI (May 6): The Kelabit community mourns the passing of veteran journalist James Alexander Ritchie, who was bestowed the Kelabit name 'Belaan Aran' (Bringer of Good News) in recognition of his contributions to the community and also to the Bario Highlands. Rurum Kelabit Sarawak president Dato Dr Philip Raja said Ritchie's death was a huge loss to the community, and for him personally. He said the veteran newsman had written a book titled 'Journey into the Central Highlands of Borneo – The Kelabit Leap of Faith ', which documented the history of Baram since 1883 from a local perspective. 'I don't think anyone else after this will get to write such a comprehensive and detailed account of the achievements and contributions of the Kelabit community and individuals to nation-building. 'On behalf of our community, I truly thank him for recording all these for historical context in perpetuity,' he said. Ritchie's Kelabit name, Belaan Aran, was bestowed by Philip's late uncle, Pemanca Jala. Philip recalled he first had contact with Ritchie in 1993 after he returned from the UK, having passed his MRCP (UK) diploma, and began serving as a paediatrician at the Sarawak General Hospital (SGH) in Kuching. He said Ritchie had struck him as seemingly very knowledgeable about new happenings within the Kelabit community, as the journalist later wrote about him (Philip) being the first native in Sarawak to become a paediatrician. 'He also wrote an article in the New Straits Times about the sacrifice of my grandfather Makai Ulun, who believed so much in education that he walked through jungles from Bario to Long Lellang for one week and took another week by river to Marudi to send my father Petrus Lawai Busan off to study at St Thomas' School in Kuching. 'Without such sacrifices, I would not be where I am today, and James had always been intrigued with stories about people's struggles. 'We mourn the loss of our dear friend and relative James Ritchie. On behalf of the Kelabit community, we extend our deepest and heartfelt condolences to his wife, daughter and family,' said Philip. Ritchie passed away last Saturday, aged 75. condolences Dr Philip Raja James Alexander Ritchie Kelabit community lead
